Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
$INCY
Sector
Primary listing
Employees
2,617
Headquarters
Website
Incyte Metrics
BasicAdvanced
$16B
19.02
$4.37
0.72
-
Price and volume
Market cap
$16B
Beta
0.72
52-week high
$87.99
52-week low
$53.56
Average daily volume
1.7M
Financial strength
Current ratio
2.875
Quick ratio
2.553
Long term debt to equity
0.869
Total debt to equity
1.017
Interest coverage (TTM)
394.47%
Profitability
EBITDA (TTM)
1,059.693
Gross margin (TTM)
54.75%
Net profit margin (TTM)
18.99%
Operating margin (TTM)
21.08%
Effective tax rate (TTM)
31.02%
Revenue per employee (TTM)
$1,750,000
Management effectiveness
Return on assets (TTM)
11.52%
Return on equity (TTM)
24.30%
Valuation
Price to earnings (TTM)
19.024
Price to revenue (TTM)
3.505
Price to book
3.87
Price to tangible book (TTM)
4.15
Price to free cash flow (TTM)
16.994
Free cash flow yield (TTM)
5.88%
Free cash flow per share (TTM)
4.89
Growth
Revenue change (TTM)
18.87%
Earnings per share change (TTM)
900.04%
3-year revenue growth (CAGR)
11.36%
10-year revenue growth (CAGR)
21.68%
3-year earnings per share growth (CAGR)
0.97%
10-year earnings per share growth (CAGR)
49.74%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Bulls say / Bears say
Incyte entered a $10 million upfront collaboration with Syros Pharmaceuticals focused on discovering novel myeloproliferative neoplasm targets, securing exclusive rights and potential milestone payments up to $169 million plus royalties, significantly bolstering its core MPN pipeline (Reuters).
Total Q2 2025 product revenues rose 17% year-over-year to $1 059 million, driven by Jakafi’s 8% growth and Opzelura’s 35% jump, underscoring robust demand and operational execution (Nasdaq).
Bill Meury’s appointment as President and CEO on June 26, 2025 brings proven leadership continuity following Hervé Hoppenot’s retirement, positioning Incyte for its next growth phase (Nasdaq).
Adjusted R&D expenses (excluding acquisition costs) increased 8% year-over-year to $455.6 million in Q2 2025, reflecting elevated development spending that may pressure margins (Nasdaq).
Adjusted SG&A expenses rose 16% year-over-year to $304.8 million, driven by higher legal costs related to the Novartis contract dispute settlement, placing further strain on profitability (Nasdaq).
Key pipeline asset INCA033989 remains in Phase 1 with pivotal data not anticipated until the second half of 2025, highlighting ongoing binary risk before potential commercial upside (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Incyte News
AllArticlesVideos
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
Business Wire3 days ago
Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally
Investors Business Daily1 week ago
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $16B as of September 13, 2025.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 19.02 as of September 13, 2025.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.